med-mastodon.com is one of the many independent Mastodon servers you can use to participate in the fediverse.
Medical community on Mastodon

Administered by:

Server stats:

412
active users

#Antitumor

0 posts0 participants0 posts today

#CauliflowerMushroom - #SparassisCrispa.
One of my fave #edible & #medicinal #WildMushrooms. It's found in many places around the world, including forests on #VancouverIsland.
We #forage for these wild #mushrooms & use it in making some soups & stir fry dishes.

It's used often in #traditional #Chinese #medicine #TCM because it contains active #pharmacological ingredients. In order to study its medicinal value better, the genomic sequence of S. crispa was published in Oct 2018.
ncbi.nlm.nih.gov/pmc/articles/

Dry weight of the #basidiocarp was found to contain up to 43.6% #BetaGlucan, which was approved for the treatment of #cancer in #Japan & recommended for #COVID19 patients to overcome #inflammation.

Experiments suggest that S. crispa contains chemicals that may stimulate the #ImmuneSystem & has many #biological properties including: #AntiTumor, #antiviral activity (reverse transcriptase inhibitory activity), #neuroprotection, #cardioprotection, #AntiInflammation, #hyperlipidemia, #AntiDiabetic medication, #antimicrobial compounds, & methicillin resistant Staphylococcus aureus #MRSA.

“Personalized cancer vaccines are designed to prime the immune system so that a patient can generate a tailored antitumor response specific to their tumor mutation signature.” investors.modernatx.com/news/n

investors.modernatx.comModerna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 TrialmRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in stage III/IV melanoma patients with high risk of recurrence following complete resection Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial Companies plan to discuss results with regulatory authorities and initiate a Phase 3 study in melanoma in 2023 and rapidly expand to additional tumor types CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / December 13, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA ® ,